Nearly 30% of acquiring companies do not evaluate FCPA risks prior to an acquisition
Thomas Gregory, Ernst & Young
Advertisement
Articles by Thomas Gregory, Ernst & Young
Advertisement
Latest Updated Articles
- Risky Business: What Life Sciences Need to Know About the US Foreign Corrupt Practices Act Before an Acquisition
Published: November 8th 2009 | Updated:
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
US News & World Report Reveals 2026 Best Medicare Advantage and Part D Companies
2
Cold Chain Technologies, Teva, and Kuehne+Nagel Proves Sea Freight Viable for High-Value Pharma Shipments
3
AstraZeneca Expands Texas Manufacturing Facility to Double Production of Hyperkalemia Drug
4
HDA 2025 Traceability Seminar: Pharma Supply Chain Nears Full DSCSA Compliance
5
